NeuroHeal

Executive Summary

NeuroHeal is a clinical-stage biopharmaceutical company pioneering regenerative therapies for neurological injuries and diseases. Founded in 2017 and headquartered in Cambridge, MA, the company has raised over $520 million to advance its pipeline of novel small molecules designed to promote nerve repair and protect neuronal function. NeuroHeal's lead programs target substantial unmet needs in spinal cord injury (SCI), traumatic brain injury (TBI), and neurodegenerative diseases. The company is currently in Phase 2 clinical trials for its lead candidate, NH-101, for acute SCI, with topline data expected within the next 12-18 months. A successful readout could de-risk the program and pave the way for a pivotal Phase 3 trial. Beyond SCI, NeuroHeal is exploring NH-101 in TBI and has preclinical programs targeting Alzheimer's and Parkinson's diseases. The company's differentiated approach—focusing on small molecules that cross the blood-brain barrier and stimulate intrinsic repair pathways—offers potential advantages over cell-based or gene therapies. With a strong balance sheet and experienced management team, NeuroHeal is well-positioned to execute on its upcoming milestones. However, the inherent risks of Phase 2 development in neurology, including high placebo response rates and regulatory uncertainty, temper enthusiasm. NeuroHeal's progress over the next year will be critical in determining its trajectory as a leader in neuroregeneration.

Upcoming Catalysts (preview)

• Q3 2027Phase 2 topline data for NH-101 in spinal cord injury35% success
• Q2 2027Initiation of Phase 2 trial for NH-101 in traumatic brain injury80% success
• Q4 2026Strategic partnership or licensing deal for non-core assets50% success